We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Patient Death Prompts Biogen, Elan to Pull MS Drug Tysabri From Market
Patient Death Prompts Biogen, Elan to Pull MS Drug Tysabri From Market
February 28, 2005
Biogen Idec and Elan suspended sales of their multiple sclerosis (MS) drug Tysabri Feb. 28 following reports that the product might have contributed to a pair of serious adverse events, including one patient death.